All In Biotech

Drug Trial Radar · NCT05973773

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

285

Actual

Start

Dec 18, 2023

Primary completion

May 27, 2027

Study completion May 27, 2027

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.

Conditions

  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Interventions

  • TAS6417Drug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and B: The rate and severity of treatment emergent AEsTime frame: approximately 5 years
  2. Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)Time frame: approximately 5 years
  3. Part A: The rate and severity of DLTs according to the NCI-Common Terminology Criteria of Adverse Events (CTCAE) v5.0 during Cycle 1Time frame: approximately 5 years

Locations

110 sites in 22 countries. Site status is shown where the registry gives one.

  • Comprehensive Cancer Centers of Nevada - Henderson

    Henderson, Nevada

  • Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie

    Henderson, Nevada

  • Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II

    Las Vegas, Nevada

  • Comprehensive Cancer Centers of Nevada - Southwest

    Las Vegas, Nevada

  • Comprehensive Cancer Centers of Nevada - Central Valley - Twain

    Las Vegas, Nevada

  • Comprehensive Cancer Centers of Nevada - Northwest

    Las Vegas, Nevada

  • Gabrail Cancer and Research Center

    Canton, Ohio

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Flemish Brabant, Belgium

  • Algemeen Ziekenhuis Maria Middelares

    Ghent, Oost-Vlaaderen, Belgium

  • Algemeen Ziekenhuis Delta - Campus Menen

    Menen, West Flanders, Belgium

  • Algemeen Ziekenhuis Delta - Campus Rumbeke

    Rosières, West-Vlaanderen, Belgium

  • Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Hospital Mãe de Deus - Centro Integrado de Oncologia

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital São Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clínica Neoplasias Litoral

    Itajaí, Santa Catatina, Brazil

  • Hospital Amaral Carvalho

    Jaú, São Paulo, Brazil

  • BC Cancer Vancouver

    Vancouver, British Columbia, Canada

  • William Osler Health System - Brampton Civic Hospital

    Brampton, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • CentroEstudiosClinicosSAGA

    Santiago, Region de Santiago, Chile

  • Hospital Clínico Universidad de Chile

    Independencia, Santiago Metropolitan, Chile

  • CH Cornouaille Quimper

    Quimper, France

  • Les Hôpitaux Universitaires de Strasbourg

    Strasbourg, Alsace, France

  • Hôpital Côte De Nacre

    Caen, Basse-Normandie, France

  • Hôpital Ambroise-Paré

    Boulogne-Billancourt, Île-de-France Region, France

  • Institut Curie

    Paris, Île-de-France Region, France

  • Centre Hospitalier Universitaire Limoges

    Limoges, Limousin, France

  • LMU Klinikum - Campus Innenstadt

    München, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Germany

  • Universitätsklinikum Gießen und Marburg - Gießen

    Giessen, Hesse, Germany

  • General Hospital for Thoracic Diseases Sotiria

    Athens, Attica, Greece

  • Emek Medical Center

    Afula, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Assuta Hospital - Ramat HaHayal

    Tel Aviv, Israel

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

    Milan, Italy

  • Azienda Ospedaliero - Universitaria di Modena

    Modena, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Azienda Unità Sanitaria Locale della Romagna

    Ravenna, Italy

  • IRCCS Istituto Nazionale Tumori Regina Elena

    Roma, Italy

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.